NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
Reveal Pharmaceuticals Inc.
University of Alabama at Birmingham
The University of Texas Health Science Center, Houston
Corewell Health West
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)